BofA analyst Tazeen Ahmad lowered the firm’s price target on Neurocrine (NBIX) to $190 from $195 and keeps a Buy rating on the shares. The firm, which says it continues to be encouraged by Ingrezza’s commercial performance, sees a long revenue runway for the franchise.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine price target raised to $151 from $149 at Wedbush
- Neurocrine price target lowered to $173 from $175 at Morgan Stanley
- Reaffirming Buy: Solid Core Franchise Execution and Underappreciated Pipeline Upside Support Mid-$150s Valuation
- Neurocrine Biosciences: Durable Ingrezza Franchise and Emerging Crenessity Uptake Support Buy Rating and $190 Price Target
- Neurocrine price target raised to $204 from $203 at Citi